NF1 and melanoma: Mutations in NF1 are enriched in melanoma that have wild-type BRAF and NRAS (25% of those had NF1 mutations as reported by Hodis [32], albeit a relatively small number of patients was analyzed), suggesting that they could be considered as driver mutations in this subset that was, until now, not amenable to targeted therapy approaches.